Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide

Kok Fei Chan,1,2,3,4 Benjamin S. Gully,3,5 Stephanie Gras,3,5 Dennis X. Beringer,3 Lars Kjer-Nielsen,2 Jonathan Cebon,1 James McCluskey,2 Weisan Chen,1,4 & Jamie Rossjohn,3,5,6

Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8–10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4+TRAJ8+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B*07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72+HLA-B*07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR–pHLA-I interface engenders recognition.
Human leukocyte antigen (HLA)-I molecules are of central importance in the presentation of antigenic peptides, enabling CD8\(^+\) T cells to eliminate cancerous and virally infected cells. Typically, HLA-I molecules present peptides between 8 and 10 amino acids in length, where the N- and C-termini of the peptide are fixed within the P2 and P1\(^+\) binding pockets of the antigen (Ag)-binding cleft, respectively. However, HLA-I molecules can present extended peptides (>10 amino acids), whereby the N- and C-termini are similarly constrained within the HLA-I molecule, forcing the central region of the peptide to bulge from the Ag-binding cleft. In addition, the HLA-associated peptide repertoire may be further expanded via N-terminal extensions on presented peptides, as observed for HLA-B*57:01. C-terminal protrusions have also been observed and were shown to extend out of the F pocket of the HLA-I binding groove. Collectively, it has been estimated that extended peptides could comprise as much as 10% of the total HLA-I peptide repertoire. Accordingly, it is difficult to predict a priori how extended peptides will be accommodated within the HLA-I molecule, and subsequently recognised by the T-cell receptor (TCR). Nevertheless, a number of studies have reported the importance of extended peptides in CD8\(^+\) T-cell-mediated immunity—mostly in the axis of viral immunity. Extended peptides presented by HLA-I molecules can adopt highly dynamic conformations, thereby presenting differing energetic barriers for TCR ligation. Extended peptides are generally considered to be challenging targets for TCR recognition owing to the dynamic nature of the central bulge in contrast to peptides of canonical length. Extended peptides were frequently associated with highly biased T-cell repertoire and thought to be resultant from conserved and HLA-I-centric TCR docking topologies, enabling CD8\(^+\) T cells to eliminate cancerous and virally infected cells. Typically, HLA-I molecules present peptides from infected cells. Generally considered to be challenging targets for TCR recognition, HLA-I-centric TCR docking topologies were frequently associated with highly biased T-cell repertoire, and NY-ESO-1 restricted peptides could comprise as much as 10% of the total HLA-I peptide repertoire. Nevertheless, a number of studies have reported the importance of extended peptides in CD8\(^+\) T-cell-mediated immunity—mostly in the axis of viral immunity.

**Results**

**NY-ESO-1\(^{60–72}\)-HLA-B*07:02-specific CD8\(^+\) T-cell clonotypes.** To investigate the basis of extended peptide reactivity by polyclonal T cells from diverse TRBV families, we isolated and expanded NY-ESO-1\(^{60–72}\)-HLA-B*07:02 reactive CD8\(^+\) T cells from peripheral blood mononuclear cells (PBMC) of patients with melanomas expressing NY-ESO-1. Following vaccination with NY-ESO-1 protein formulated with ISCOMATRIX\(^\text{TM}\) adjuvant, an expansion of CD8\(^+\) T cells were observed at day 71, and persisted to day 197 post vaccination following in vitro stimulation with NY-ESO-1(55–72) peptide. Intracellular cytokine staining (ICS) measuring interferon-\(\gamma\) (IFN-\(\gamma\)) production was used to identify and enumerate the NY-ESO-1(55–72)-HLA-B*07:02 reactive cells within this expanded CD8\(^+\) T-cell pool (Fig. 1a). Previous peptide screening studies identified NY-ESO-1\(^{60–72}\) as the active 13-amino-acid epitope. Thus, T cell specificity for NY-ESO-1\(^{60–72}\)-HLA-B*07:02 in the expanded CD8\(^+\) T-cell pool was determined by tetramer staining. A similar trend in NY-ESO-1\(^{60–72}\)-HLA-B*07:02 tetramer-positive T cells was seen post vaccination as for IFN-\(\gamma\) production within the T-cell pool (Fig. 1b). Further, CD3\(^+\) CD8\(^+\) NY-ESO-1\(^{60–72}\)-HLA-B*07:02 tetramer-positive T cells were single cell sorted and expanded. TRBV gene usage of the T-cell clones was determined using a panel of V\(\beta\) specific antibodies (Supplementary Fig. 1a) and in-depth analysis of the paired \(\alpha\)- and \(\beta\)-chain TCR gene usage of the sorted cells was done using TCR gene sequencing. To determine the paired \(\alpha\)- and \(\beta\)-chain TCR gene usage of the isolated cells, TCR gene sequencing on four selected clones was performed (Table 1). Notably, no consensus motif/TCR bias was evident within the NY-ESO-1\(^{60–72}\)-HLA-B*07:02-reactive TCR sequences in contrast to TCRs previously shown to recognise other extended peptides.

**Characterisation of NY-ESO-1\(^{60–72}\)-HLA-B*07:02 reactivity.** To confirm the NY-ESO-1\(^{60–72}\) reactivity of the HLA-B*07:02 restricted CD8\(^+\) T-cell clones, we selected four clones, all of which bound the NY-ESO-1\(^{60–72}\)-HLA-B*07:02 tetramer (Fig. 1c). The clones represented a cross-section of the TCRs and TCR\(\beta\) gene usage. These clones, KFJ4 (TRAV13-1 TRAJ32-1 TRAJ20-1 TRAJ21-1), KFJ5 (TRAV44 TRAJ21-1 TRBV22 TRBD1 TRBD1), KFJ15 (TRAV17 TRAJ20-1 TRBV6-1 TRBD1 TRBD2-7), and KFJ37 (TRAV44 TRAJ8-1 TRBV9 TRBD1 TRBD2-11), and suitable controls (the HLA-B*08:01-restricted TCR, LC13) were

---

**ARTICLE**

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03321-w | www.nature.com/naturecommunications

© 2018 Springer Nature Limited. All Rights Reserved.
Fig. 1 Functional reactivity of CD8+ T cells binding to HLA-B*07:02 presenting NY-ESO-106–72. a Flow cytometry analysis of melanoma patient’s PBMCs showing CD8+ T-cell expansion pre- (Day 0) and post- (Days 71 and 197) NY-ESO-1-ISCOMATRIX™ vaccination following in vitro stimulation with NY-ESO-1055–72 peptide as assayed by intracellular cytokine staining (ICS) measuring interferon-γ (IFN-γ) production. b Flow cytometry analysis showing a distinct NY-ESO-106–72-HLA-B*07:02 reactive CD8+ T-cell population following vaccination and in vitro stimulation with NY-ESO-1-055–72 peptide. Four functionally distinct NY-ESO-106–72-HLA-B*07:02-specific CD8+ T-cell clones were identified from the melanoma patient’s PBMCs. c NY-ESO-106–72-HLA-B*07:02 tetramer-positive CD8+ T-cell clones were generated from single-cell cloning. d Four NY-ESO-106–72-HLA-B*07:02-specific TCRs were retrovirally reconstituted in SKW3 cells and recognised NY-ESO-106–72-HLA-B*07:02 presented on peptide-pulsed HLA-B*07:02+ antigen-presenting cells (APCs). The overlaid flow cytometry histograms of CD69 up-regulation in CD69+ TCR-transduced SKW3 cells following co-incubation with NY-ESO-1-06–72 peptide-pulsed (blue histogram) or non-pulsed APCs (red histogram). The SKW3 subsets were gated on live lymphocytes, CD3hi GPhi markers and were subsequently displayed as % of max (Y-axis) versus CD69 (X-axis). LC13 TCR-transduced SKW3 cells served as a TCR positive but nonreactive control as we have shown it recognises the EBNA-3A133–147 peptide-pulsed HLA-B*08:01+ APCs and up-regulated CD69 surface marker64. A second independent retroviral transduction experiment was performed for the KFJ4 (TRAV13), KFJ4 (TRAV26), KFJ37 and LC13 TCRs, with consistent results, see Supplementary Fig. 4. e Four different NY-ESO-106–72-HLA-B*07:02-specific T-cell clones were individually co-incubated with HLA-B*07:02+ and NY-ESO-1-expressing SK-Mel-14 cells in 1:2 ratio in the presence of 10 μg mL−1 of Brefeldin A for 5 h to detect naturally presented NY-ESO-106–72-HLA-B*07:02. CD8+ T-cell clone recognition of naturally presented NY-ESO-106–72-HLA-B*07:02 on NY-ESO-1-expressing melanoma cell line, SK-Mel-14. CD8+ T-cell responses were assayed by ICS measuring IFN-γ production. f Functional sensitivity of the CD8+ T-cell clones to exogenous NY-ESO-106–72 peptide at different concentrations. CD8+ T-cell clones that are sensitive to lower levels of antigen are considered to possess high avidity.

used to generate a panel of TCR-transduced SKW3 T-cell lines. With the exception of the TRAV26-1+ KFJ4-SKW3 cells, these TCR-SKW3 cell lines up-regulated the T-cell activation marker CD69 upon stimulation with NY-ESO-106–72 peptide-pulsed HLA-B*07:02+ antigen-presenting cells (APCs) (Fig. 1d). The KFJ4 T-cell clone carried two productive rearrangements of the TCR α-domain (Table 1) as identified in ~30% of T cells35, yet only the TRAV13-1+ TRAJ37+ α-chain (paired with TRBV10-3+ TRBD1+ TRBJ1-2+ γ3-chain) formed a functional NY-ESO-106–72-HLA-B*07:02 restricted TCR (Fig. 1d). The four functional
CD8+ T-cell clones were confirmed to recognise naturally presented NY-ESO-1α0-72-HLA-B*07:02 on the surface of SK-Mel-14 melanoma cells, as measured by induction of IFN-γ production (Fig. 1e). We then compared the functional reactivity of the TCR clones upon titrated NY-ESO-1α0-72-peptide-pulsed APC stimulation. All four TCRs induced IFN-γ production at very low peptide concentrations (≤10-9 M) (Fig. 1f). Interestingly, the KFJ15 clone elicited a lower avidity response, consistent with the reduced level of staining (Fig. 1e) and faster dissociation (Supplementary Fig. 1b) of the NY-ESO-1α0-72-HLA-B*07:02 tetramer.

To characterise the fine specificity of the identified T-cell clones specific to the NY-ESO-1α0-72-HLA-B*07:02 complex on T-cell reactivity, we conducted an alanine-scanning assay. Here, the four T-cell clones displayed reduced reactivity to centrally mutated peptides (P4-Gly→P8-Gly), indicating the importance of the central region of the NY-ESO-1α0-72 peptide (Fig. 2a and Supplementary Fig. 2) in TCR recognition. Interestingly, the tolerance of KFJ5 and KFJ37 T-cell clones towards the P3-Arg mutation differed, with KFJ37 retaining ~90% of reactivity, whereas KFJ5 reactivity was completely ablated (Fig. 2a and Supplementary Fig. 2), suggesting that the KFJ5 and KFJ37 TCRs focused on the central region of the NY-ESO-1α0-72 peptide presented by HLA-B*07:02 with differing fine specificities. We then examined the CD8 dependency of these TCRs, with each T-cell clone showing reduced activation when stimulated by NY-ESO-1α0-72 peptide in the presence of a blocking CD8 antibody. This effect was most pronounced at low peptide concentrations (Supplementary Fig. 3) and served to highlight the importance of CD8 in NY-ESO-1α0-72-HLA-B*07:02 restricted T-cell activation.

CD8+ T-cell clones with higher avidity for NY-ESO-1α0-72-HLA-B*07:02 tetramer (Supplementary Fig. 1f) correlated well with their activation by lower peptide concentration (Fig. 1f) and by melanoma cells (Fig. 1e). Thus, fine specificity analysis indicated that the four TCRs exhibited different modes of interaction within the common central region of the NY-ESO-1α0-72 epitope.

Affinities for the NY-ESO-1α0-72-HLA-B*07:02 complex. We next determined the affinity of the four TCRs towards the NY-ESO-1α0-72-HLA-B*07:02 complex using surface plasmon resonance (SPR). Soluble ectodomains of the KFJ4, KFJ5, KFJ15 and KFJ37 TCRs, as well as the NY-ESO-1α0-72-HLA-B*07:02 complex were expressed, refolded and purified46,47. As expected, the KFJ4, KFJ5, KFJ15 and KFJ37 TCRs did not bind to the control pHLA complex. The KFJ4, KFJ5 and KFJ37 TCRs bound to NY-ESO-1α0-72-HLA-B*07:02 with an affinity (Kd) of 40–50 μM (Fig. 2b, c). In contrast, the KFJ5 TCR bound with a markedly reduced affinity of >200 μM, suggesting greater structural challenges to TCR binding48-52. We next investigated the binding kinetics by determining the on-rate (k_on), which were only measurable for the KFJ4 and KFJ37 TCRs. These values appeared notably slow when compared to the SPR sensograms and equilibrium binding curves (Fig. 2b, c) to other TCR-binding studies48-52. Similarly, the SPR sensograms for the KFJ5 and KFJ15 TCRs show a similarly pronounced slow association rate. The slow on-rates of these TCRs further suggest that TCR or peptide conformational rearrangements may be required for NY-ESO-1α0-72 recognition, in contrast to TCR recognition of the rigid super-bulged LPEP peptide presented by HLA-B*27:0548,49.

The NY-ESO-1α0-72 peptide adopts a bulged conformation. To evaluate presentation of the NY-ESO-1α0-72 peptide by HLA-B*07:02, we determined the structure of HLA-B*07:02 presenting the NY-ESO-1α0-72 peptide to a resolution of 1.5 Å, which was significantly higher than the 2.1 Å resolution structure reported previously48 (Table 2). Superimposition of the HLA-B*07:02 molecule onto the structure of HLA-B*07:02 bound to a nona-meric RFL9 peptide53 illustrated little movement in the HLA-I molecule (root-mean-squared deviation (r.m.s.d.) of 0.2 Å) (Fig. 2e), despite presenting distinct peptides. Given the anchored restraints at the peptide extremities, the central residues, encompassing P4-Gly→P11-Ser of the NY-ESO-1α0-72 peptide, bulged extensively out of the peptide-binding groove. Here, the solvent accessible surface area of the NY-ESO-1α0-72 peptide was double that of the RFL9 peptide (620 Å2 compared to 290 Å2), thereby providing an extended surface for TCR-mediated recognition. Notably, although solved to high resolution, P6-His-P8-Gly side chains were not clearly observed in the electron density (Fig. 2d), which suggested conformational plasticity in this region of the peptide.

Overview of TCR-NY-ESO-1α0-72-HLA-B*07:02 complexes. Next, we determined the structure of the KFJ5 and KFJ37 TCRs complexed to NY-ESO-1α0-72-HLA-B*07:02 (Table 2). The well-defined electron density at the respective TCR-NY-ESO-1α0-72-HLA-B*07:02 interfaces enabled the ternary complexes to be readily refined and interpreted. The KFJ37 TCR and KFJ5 TCR adopted similar and canonical docking modes, binding centrally atop the pHLA-I (Fig. 3a, b), with a docking angle of approximately 70° across the peptide-binding groove of HLA-B*07:02, whereby the Va and Vβ of the TCR positioned over the α2- and α1-helices, respectively (Fig. 3d, e). In comparison to the KFJ15 TCR ternary complex, the KFJ5 TCR was shifted by ~2.5 Å towards the α1-helix, resulting in the Va chain docking more centrally above the peptide-binding groove and the Vβ3 chain positioning more peripherally (Fig. 3e). The docking modes observed here differed notably from the SB27 TCR recognition of the LPEP-HLA-B*27:05 complex (Fig. 3c). Here, the SB27 TCR adopted a 90° docking angle and bound towards the N-terminus of the α2-chain, which was not possible for the KFJ5 and KFJ37 TCRs.
Fig. 2 NY-ESO-1p10–72 peptide specificities and steady-state affinities for CD8+ T-cell clones. a Normalised data for IFN-γ production by different CD8+ T-cell clones when stimulated with 10−7 M concentration of native NY-ESO-1p10–72 peptide (APRGPAGGGAAGSL) or single alanine-substituted peptides. CD8+ T cell responses stimulated by native peptide for each clones were accorded as 100%, and other CD8+ T cell responses stimulated by single alanine-substituted peptides were calculated as a relative percentage to the native peptide responses. CD8+ T cell responses stimulated by different single alanine-substituted peptides concentrations are shown in Supplementary Fig. 2. Surface plasmon resonance sensorsgrams (b) and equilibrium binding curves (c) showed that the in vitro refolded and purified recombinant TCRs (immobilised at ~300–350 response units) interacted with NY-ESO-1p10–72-HLA-B*0702 (screened at serial dilutions from 200 to 0 μM). SPR sensorsgrams are representative of a single experiment. Equilibrium binding curves were derived from two replicate experiments with K_on, K_off, and equilibrium curve means calculated from the duplicate experiments (error and error bars denote SEM). d The observed electron density (ZnFe-DFz), shown as blue mesh, for the NY-ESO-1p10–72 peptide contoured to 1σ illustrates the structural flexibility and kinkiness of the central peptide residues (P6-His-P8-Gly). e NY-ESO-1p10–72 adopts a bulged conformation upon presentation by HLA-B*0702. Comparison of the NY-ESO-1p10–72-HLA-B*0702 bulged peptide presentation with the RL9-HLA-B*0702 peptide presented in a canonical fashion (PDB: 5EO1). The heavy chain is shown in grey with the NY-ESO-1p10–72 and RL9 peptides shown in black and red, respectively.
of the LPEP peptide and made limited contacts with the HLA-I molecule (Fig. 3f, i)21. The total buried surface area (BSA) of the KFJ37 TCR-NY-ESO-1\textsubscript{160–72}–HLA-B\textsuperscript{*}07:02 interface was 2330 Å\textsuperscript{2}, of which the TCR α- and β-chains contributed approximately equally (45% and 55%, respectively) (Fig. 3g). The KFJ37 TCR NY-ESO-1\textsubscript{160–72}–HLA-B\textsuperscript{*}07:02 interface comprised residues from both germline and non-germline residues with each CDR loop of the α-chain (20%, 7%, 15% and 1% BSA from the CDR1α, CDR2α, CDR3α and FW, respectively) and β-chain (2%, 18%, 26% and 9% BSA from the CDR1β, CDR2β, CDR3β and FW, respectively) contributing to HLA-B\textsuperscript{*}07:02 recognition (Fig. 3g). Here, Asn31α and Tyr33α (CDR1α) projected down towards the HLA-I surface and formed hydrogen bonds to Arg62 and Trp167, and Ala158, Tyr159 and Glu163 of the HLA-I, respectively (Fig. 4a and Supplementary Table 1). The CDR1α contacts to the HLA-I surface were further stabilised via extensive van der Waals contacts involving Asn31α and Tyr33α, in addition to Thr30α contacting Glu163, Glu166, Trp167 of the HLA-I α2-helix. Further, Lys58α (CDR2α) formed a hydrogen bond to Glu161 of the HLA-I α2-helix. Additionally, Asp108α (CDR3α) formed a salt bridge with Arg62 of the α1-helix (Fig. 4a and Supplementary Table 1). The β-chain of the KFJ37 TCR makes further ionic interactions with the HLA-I α1-helix, whereby Glu59β (CDR2β) salt bridged to the protruding Arg78 (Fig. 4b and Supplementary Table 1). This interaction surface was further stabilised via hydrogen bonds from Glu60β (CDR2β) and Arg66β (FWβ) to the neighbouring residue on the α1-helix, Glu75 (Fig. 4b and Supplementary Table 1).

The total BSA of the KFJ5 TCR-NY-ESO-1\textsubscript{160–72}–HLA-B\textsuperscript{*}07:02 interface was notably smaller at 1560 Å\textsuperscript{2}. Here, the KFJ5 TCR ternary interface was dominated by TCR α-chain contacts, which contributed ~75% of the BSA. The CDR1α, CDR2α, CDR3α and FWα loops contributed 30%, 4%, 38% and 2%, respectively, to the BSA of the interface, whereas only the CDR3β of the β-chain contributed (25% BSA) to the interface (Fig. 3h and Supplementary Table 2). The KFJ5 β-chain formed limited contacts with the HLA-I surface and comprised contacts only from the CDR3β loop, including Arg109β, which contacted Thr73 and the main chain of Ala69 of the α1-helix, and Gln110β, which contacted Glu152 of the α2-helix (Fig. 4c and Supplementary Table 2). In the KFJ5 TCR ternary complex, contact to the HLA-I surface was facilitated via an extension of the F-strand of the KFJ5 Va domain over the N-terminal extremity of the α1-helix (Fig. 4d). Here the CDR3α loop is distended through the incorporation of four additional amino acids whereby the non-germline residues served to cap the peptide-binding groove of the HLA-I along with the germline Asn112α (CDR3α), which formed a hydrogen bond with Gln65 of the α1-helix (Fig. 4d and Supplementary Table 2). Given the commonality of the TRAV4*01 chains between the KFJ37 and KFJ5 TCRs, it was of interest that there were some conserved TRAV4*01-mediated contacts. Namely, Thr30α of the CDR1α made conserved van der Waals contacts to Glu163, Glu166 and Trp167 (Fig. 5f). Further, the neighbouring Asn31α made a conserved hydrogen bond to Trp167 and contacts with Arg62 (Fig. 5o). Interestingly, Tyr33α made conserved van der Waals contact to Glu163, as well as conserved coordination of P6-His (Fig. 4c, f). In addition, the TRAV4*01-encoded Thr30α and Gln55α made conserved contacts to the P6-His of the peptide (Fig. 5o). Further, non-germline commonalities included a salt-bridge contact from Asp108α to Arg62 of the HLA-B\textsuperscript{*}07:02 α1-helix (Fig. 5o). Thus, while the KFJ37 and KFJ5 TCRs share the same TRAV-encoded region and adopt a similar positioning atop the pHLA-I, the extent and details within the respective interfaces differ markedly, despite recognising the same HLA-peptide complex.

**Differential TCR recognition of the NY-ESO-1\textsubscript{160–72} peptide.** The position of the KFJ37 TCR CDR loops on the HLA-B\textsuperscript{*}07:02 surface allows the TCR to completely encapsulate the protruding NY-ESO-1\textsubscript{160–72} peptide (Fig. 4c). Indeed, the central part of the peptide was sandwiched between both CDR3 loops and three-tyrosine residues from CDR1α, FWβ and CDR2β (Supplementary Table 1). As observed in the binary structure, the central portion of the NY-ESO-1\textsubscript{160–72} peptide arched out of the peptide-binding groove, yet here was stabilised upon KFJ37 TCR ligation (Fig. 4c). Namely, the central region (P6-His–P9-Ala) of the NY-ESO-1\textsubscript{160–72} peptide formed extensive contacts with the KFJ37 TCR. Here, P6-His made hydrogen bonding contacts with Tyr33α of the CDR1α loop and Gln55α of the FWα (Fig. 4c and Supplementary Table 1) and also made a water-mediated contact to Ser113β of the CDR3β. The bulging peptide was further stabilised by Ser107β and Ser113β of the CDR3β loop, which formed hydrogen bonds to the peptide main chain at positions P9-Ala, and P8-Gly, respectively, in addition to numerous van der Waals contacts to the peptide (Fig. 4c and Supplementary Table 1). Indeed, the bulging peptide comprised 36% of the interaction surface (BSA) for KFJ37 TCR-mediated HLA-B\textsuperscript{*}07:02 recognition, comparable to the ~41% contribution to peptide-mediated recognition in SB27 TCR12.

In stark contrast, the NY-ESO-1\textsubscript{160–72} peptide underwent dramatic remodelling upon recognition by the KFJ5 TCR, due in part to the steric occlusion from the distended CDR3α loop and the coordination of the CDR3β loop. Here, the super-bulged NY-ESO-1\textsubscript{160–72} topology was deformed upon KFJ5 TCR ligation and adopted a ‘helical’ peptide conformation (P5-P8) (Fig. 4f), the impact of which resulted in a relatively flattened epitope upon KFJ5 TCR engagement, which in turn resulted in a markedly reduced (~20%) contribution to the interaction surface. Peptide recognition in the KFJ5 TCR ternary complex was almost entirely modulated via van der Waals interactions, notwithstanding the solitary hydrogen bond to the peptide from Asp113β of the CDR3β to P6-His, which flipped 180° into an upright conformation, compared to the KFJ37 TCR complex, while retaining contacts with Tyr33α of the CDR1α (Fig. 4f and Supplementary Table 1). The large deformation of the bulged peptide is coordinated via water-mediated interactions from the KFJ5 TCR CDR3 loops with Glu108α and Gln110β serving to stabilise the helical peptide main chain at P6-His and P5-Pro, respectively (Fig. 4f and Supplementary Table 2). Van der Waals interactions included Glu108α, Ile109α and Leu110α of the CDR3α, to P4-Gly and P5-Pro of the peptide, which further contributed to the reduced (~20%) contribution to the interaction surface. Peptide recognition in the KFJ5 TCR ternary complex was almost entirely modulated via van der Waals interactions, notwithstanding the solitary hydrogen bond to the peptide from Asp113β of the CDR3β to P6-His, which flipped 180° into an upright conformation, compared to the KFJ37 TCR complex, while retaining contacts with Tyr33α of the CDR1α (Fig. 4f and Supplementary Table 1). The large deformation of the bulged peptide is coordinated via water-mediated interactions from the KFJ5 TCR CDR3 loops with Glu108α and Gln110β serving to stabilise the helical peptide main chain at P6-His and P5-Pro, respectively (Fig. 4f and Supplementary Table 2).

Superimposition of the two-peptide conformations revealed an r.m.s.d. value of 3.6 Å over the 81 atoms of the peptide, representing a considerable remodelling (Fig. 5a–d). While the N-terminus of the NY-ESO-1\textsubscript{160–72} peptides remained unchanged from P1-Ala–P5-Pro (Fig. 5a–d), the coordination chemistry of the peptide backbone shifted drastically through positions P6-His, P7-Gly, P8-Gly and P9-Ala with the α-carbon of each residue moving 3.1, 9.7, 9.6 and 7.2 Å, respectively (Fig. 5e). Taken together, these structures indicated that the NY-ESO-1\textsubscript{160–72} peptide was highly malleable prior to engagement by two cognate TCRs.

**Peptide plasticity is complemented by TCR malleability.** To further understand the remodelling at the TCR-NY-ESO-1\textsubscript{160–72}–HLA-B\textsuperscript{*}07:02 interface, the conformational plasticity of the peptide was modelled using the STAPLE22 program, revealing a significant conformational flexibility throughout its length (Fig. 5f). This flexibility is complemented by the TCR malleability, as revealed through extensive repositioning of the CDR loops (Fig. 4). The overall repositioning was dominated by two main motifs: (1) cooperative remodelling of the CDRs (Fig. 4a, c, i, k, n), and (2) cooperative remodelling of the α and β chains (Fig. 4b, d, j, l, o, p).

**Conclusion.** A design of TCRs for recognising conserved epitopes in NY-ESO-1 presents a unique opportunity to test the fundamental roles of TCR malleability and antibody-TCR cross-talk. By identifying the key residues that affect the structure and conformation of the peptide and the TCR, we can design a more effective and robust TCR for such epitopes.
1. A more modest remodelling was observed within the CDR regions of the KFJ5 TCR in an unligated form (Table 2). When comparing the KFJ5 TCR to an unligated and ligated form (Supplementary Fig. 3a), the CDR regions underwent significant remodelling. A large movement of the CDR3α was observed in which residues Glu108 and Glu109 moved ~9 Å upon recognition of the NY-ESO-1-160-72–HLA-B*07:02 complex. This same epitope was recognised differently by a distinct TCR, the CF34 and LC13 TCRs docked towards the N-terminus and C-terminus of the NY-ESO-1-160-72 peptide. The remodelling suggests that the structural plasticity of extended epitopes can be accommodated to some extent by complementary remodelling of the TCR, but at an energetic cost, as illustrated by the reduced RCD of the KFJ5 TCR.

2. The structural basis for which distinct TCRs can recognise the same pHLA-I complex has been described1,2,16,51–55. Two TCRs (A6 and B7) bound Tax-HLA-A*02:01 in a largely conserved docking mode despite differing TRAV gene usage. Similarly, three TCRs (H27-14, T36-5 and CI-28)53 and two TCRs (DMF4 and DMF5)55, which utilised varied TRAV and TRBV gene segments, recognised RFP-HLA-A*24:02 and MART-1-HLA-A*02:01, respectively, with a conserved docking mode51,53. In both cases the variation at the TCR–pHLA-I interface contributed to altered interatomic contacts thereby providing a molecular basis for differing TCR functional responses to pHLA-I stimulation. In contrast, varied TCR gene usage directed against FLR347, an antigen of importance in onco-immunology given its tumour-dependent expression and growing importance as a therapeutic target9,35,51,52.

3. Here, the RL42 TCR employed a central docking mode, whereas the CF34 and LC13 TCRs docked towards the N-terminus and C-terminus of the peptide, respectively53. Two TCRs (A6 and B7) bound Tax-HLA-A*02:01 in a largely conserved docking mode despite differing TRAV gene usage. Similarly, three TCRs (H27-14, T36-5 and CI-28)53 and two TCRs (DMF4 and DMF5)55, which utilised varied TRAV and TRBV gene segments, recognised RFP-HLA-A*24:02 and MART-1-HLA-A*02:01, respectively, with a conserved docking mode51,53. In both cases the variation at the TCR–pHLA-I interface contributed to altered interatomic contacts thereby providing a molecular basis for differing TCR functional responses to pHLA-I stimulation. In contrast, varied TCR gene usage directed against FLR347, an antigen of importance in onco-immunology given its tumour-dependent expression and growing importance as a therapeutic target9,35,51,52.

Table 2 Data collection and refinement statistics

| Data collection | KFJ5 TCR | NY-ESO-160-72–HLA-B*07:02 | KFJ5 TCR–NY-ESO-160-72–HLA-B*07:02 | KFJ37 TCR–NY-ESO-160-72–HLA-B*07:02 |
|----------------|---------|---------------------------|-----------------------------------|-----------------------------------|
| Temperature (K) | 100 | 100 | 100 | 100 |
| Space group | P2; 2, 2_1, 2 | P2; 2, 2_1, 2 | P2; 2, 2_1 | P1 |
| a, b, c (Å) | 49.90, 73.36, 123.04 | 50.19, 82.07, 112.05 | 64.36, 67.69, 105.72 | 74.41, 66.66, 96.28 |
| a, b, c (°) | 90, 90, 90 | 90, 90, 90 | 90, 102.93, 90 | 94.22, 97.88, 90 |
| Resolution range (Å) | 46.25–1.42 (1.49–1.42) | 46.27–1.50 (1.58–1.50) | 46.01–2.03 (2.14–2.03) | 47.55–2.60 (2.74–2.60) |
| I/σ(I) | 7.4 (48.7) | 12.1 (56.4) | 11.0 (57.9) | 13.9 (68.3) |
| Completeness (%) | 99.4 (97.8) | 99.7 (100.0) | 99.1 (96.8) | 98.8 (98.2) |
| Redundancy | 7.0 (6.8) | 6.9 (7.2) | 3.7 (3.7) | 3.9 (3.9) |
| Total observations | 603,854 (82,919) | 577,968 (77,738) | 211,802 (29,607) | 217,862 (31,726) |
| Unique observations | 86,034 (12,212) | 74,669 (10,830) | 57,083 (8094) | 55,997 (8124) |
| Refinement | | | | |
| Rwork (%) | 19.8 | 21.1 | 20.4 | 19.3 |
| Rfree (%) | 21.8 | 23.0 | 25.6 | 24.8 |
| No. of atoms | | | | |
| Protein | 3448 | 3191 | 6580 | 13,197 |
| Water | 618 | 912 | 447 | 561 |
| B-factors | 27.2 | 19.6 | 40.8 | 39.5 |
| Protein | 16.6 | 34.0 | 43.3 | 32.9 |
| R.m.s. deviations | | | | |
| Bond lengths (Å) | 0.007 | 0.005 | 0.006 | 0.004 |
| Bond angles (°) | 1.096 | 0.952 | 1.171 | 1.050 |

1. Values in parentheses are for the highest-resolution shell.

2. Rfree = Σ||Fo||–||Fc||/Σ||Fo|| for all data excluding the 5% that comprised the Rwork used for cross-validation.

Polyclonal CD8+ T cell response to HLA-B*07:02 presenting the immunodominant NY-ESO-160–72 peptide, which was detected in patients with melanomas expressing NY-ESO-157, an antigen of importance in onco-immunology given its tumour-dependent expression and growing importance as a therapeutic target9,35,51.
mode, whereby the bulged peptide was flattened upon TCR ligation. Although the identified NY-ESO-1<sub>60–72</sub>-HLA-B<sup>*07:02</sup> restricted T-cell population was characterised by a diverse TCR gene repertoire, the KFJ37 and KFJ5-TCRs utilised the same TRAV4*01 gene. In spite of differing peptide conformers being recognised by alternate peptide docking modes there were some vestiges of conserved pairwise germline contacts between the TRAV4*01-encoded TCR α-chain and the HLA-B<sup>*07:02</sup> molecule and the peptide itself.

Our ternary structures highlighted the extent to which TCR plasticity can be harnessed by the adaptive immune system to evoke an immune response. Our findings provide novel insight into the recognition of extended peptide epitopes via distinct T-cell populations, and highlight their utilisation of widely differing docking modes to recognise an oncogenic epitope of significant clinical interest.

Fig. 3 Overview of the ternary complexes. a KFJ37 TCR-NY-ESO-1<sub>60–72</sub>-HLA-B<sup>*07:02</sup>, b KFJ5 TCR-NY-ESO-1<sub>60–72</sub>-HLA-B<sup>*07:02</sup> and c SB27 TCR-LPEP-HLA-B<sup>*35:08</sup> (PDB: 2AK4) with the TCR α- and β-chains coloured lighter and darker shades of blue, green and yellow, respectively. The HLA-B heavy chain and β<sub>2</sub>-microglobulin molecules are shown as light and dark grey, respectively. Middle and lower panels show the TCR-HLA interfaces (d–f) and footprints (g–i). The complementarity determining region (CDR) loops are coloured as follows: CDR1α light blue, CDR2α green, CDR3α teal, CDR1β orange, CDR2β red, CDR3β yellow and framework (FW) contacts are coloured pink over the HLA-B<sup>*07:02</sup> binding groove with the NY-ESO-1<sub>60–72</sub> peptide shown as black sticks. The centre of mass of the respective Vα and Vβ domains are shown as grey and black spheres, respectively. In the lower panel the molecular surface of the HLA-B molecules is shown with atomic contacts coloured according to the respective CDR-loop mediated interactions.
Methods

NY-ESO-1α, β-HEL-B07:02-specific CD8+ T-cell isolation. Patient peripheral blood cells were obtained with informed consent and the study was approved by the Human Research Ethics Committee of Austin Health (ethics approval number: H2001-01256 and title: Immunological characterisation of patients with cancer)13. PBMCs were isolated by density gradient centrifugation (Ficoll-Paque Plus, GE Healthcare). Approximately 3 × 10^6 PBMCs from days 71, 197 and 547 post-NY-ESO-1/ISCOMATRIX vaccination trial samples were pulsed with NY-ESO-1α, β peptide GPGGGAPRGPHGGAASGL (10 µg/mL), for 1 h at 37°C. The cells were then cultured in a 24-well plate in 2 mL of RPMI 1640 (Gibco) containing 10% (v/v) FCS (Thermo Trace), recombinant human IL-2 (25 U mL−1, Proleukin), Glutamax (2 mM), benzylpenicillin (100 U mL−1), streptomycin (100 µg mL−1) in 2% HEPEs buffer (10 mM), 2-mercaptoethanol (50 µM), sodium pyruvate (1 mM) and 1% nonessential amino acids (all from Gibco), harvested on days 12−15 for NY-ESO-1α, β-HEL-B07:02 tetramer staining and ICS. ICS assay was performed by stimulating CD8+ T cells with diluted synthetic peptide in 200 µL of complete RPMI 1640 medium (described above) in 10µg/mL−1 Brefeldin A (Sigma-Aldrich) and incubated for 5 h at 37°C. Cells were stained with 50 µL of PBS-diluted (1:50) antihuman CD3 and CD8 (BD Biosciences) for 30 min at 4°C. The monoclonal antibody target, clone name and source are presented in Supplementary Table S3. Cells were washed once with PBS and were resuspended in 100 µL of 1% paraformaldehyde (PFA; EMS) for 20 min at room temperature. Cells were washed once with PBS and stained with 50 µL of PBS-diluted (1:100) anti-human IFN-γ (BD Biosciences) in 0.2% saponin (Sigma-Aldrich) and incubated for 30 min at 4°C. Cells were washed once with PBS, resuspended in 100 µL PBS and analysed using FACSCanto II flow cytometer (BD Biosciences). Data were processed with FlowJo (Tree Star Inc.) software. NY-ESO-1α, β-HEL-B07:02 tetramer staining was performed by staining cells with 100 µL of PBS-diluted (1:150) NY-ESO-1α, β-HEL-B07:02 tetramer and single alanine-substituted peptides at 10 µg/mL−1 for 30 min at room temperature. Tetramers were stained at the Tetramer Production Facility of the Ludwig Institute for Cancer Research (LICR). Tetramer-stained cells (~2 × 10^6) were further stained with antibodies specific to CD3 and CD8 (BD Biosciences). Tetramer and antibodies were used at an empirically determined dilution factor with an optimum signal to noise ratio. Tetramer+CD3+CD8+ cells were individually sorted using FACSAria III flow cytometer (BD Biosciences) into a round-bottom 96-well plate containing 200 µL of complete RPMI 1640 medium (as described above but without FCS) supplemented with 10% (v/v) heat-inactivated human AB sera (LICR), 600 U recombinant human IL-2, phytohaemagglutinin (1 µg/mL−1, Sigma-Aldrich) and 3 × 10^6 healthy donors’ PBMCs (Australian Red Cross Blood Service). PBMCs were mixed from three different donors in 1:1:1 ratio before being irradiated at 3000 rad using Gammarcell 1000 Elite Irradiator 137Cs source (Nordion). The gating strategy used to sort these cells is presented in Supplementary Fig. 6a. Tetramer+CD8+ clonal cells were further expanded on day 15 post cell-sorting for another 10 to 12 days in the same setting as described above, with ~5000 clonal cells transferred into each well on a round-bottom 96-well plate initially.

Characterising the CD8+ T-cell clone TCRβ repertoire. All NY-ESO-1α, β-HEL-B07:02-specific CD8+ T-cell clones were stained with a panel of 24 antibodies specific to TCR Vβ chains (Beckman Coulter) and analysed using FACS-Canto II flow cytometer (BD Biosciences), and data were processed with FlowJo (Tree Star Inc.) software. The gating strategy used to analyse these cells is presented in Supplementary Fig. 6b.

T cells recognise NY-ESO-1α, β-HEL-B07:02 on melanoma cells. SK-Mel-14, an HLA-B*07:02+ melanoma line that expresses NY-ESO-1 antigen17 (Memorial Sloan-Kettering Cancer Centre, USA), and LM-Mel-26, an HLA-B*07:02+ melanoma line that does not express NY-ESO-1 antigen (LICR), were treated with recombinant human IFN-γ (50 ng mL−1, R&D Systems) for 48 h. CD8+ T-cell clones were co-incubated with these melanoma lines in 1:2 ratio in 10µg/mL−1 of Brefeldin A (BFA, Sigma-Aldrich) for 5 h followed by antibody staining for CD3, CD4 and CD8 (BD Biosciences), and ICS. The gating strategy used to analyse these cells is presented in Supplementary Fig. 6c. All cell lines were tested and/or treated for mycoplasma and were mycoplasma free.

Peptide titration and alanine-scanning analyses. Serial log dilutions of NY-ESO-1α, β-22 and single alanine-substituted peptides at 1 µM down to 10−12 M in RPMI-1640 medium were prepared. All peptides were synthesised with purity >95% (Mimotopes, Australia). CD8+ T-cell clones were co-incubated with LM-Mel-26 (as APCs) in 1:2 ratio in serially diluted peptide and BFA (10 µg mL−1) for 5 h followed by antibody staining and ICS (described above). The gating strategy used to analyse these cells is presented in Supplementary Fig. 6c.
were synthesised (GenScript) and subcloned into the pMIG expression vector. 4 µg pPAME was transfected into HEK 293 T cells in tissue culture medium and incubated overnight at 37 °C. About 10 million cells were seeded in tissue culture medium and incubated overnight at 37 °C. After 12 h incubation, HEK 293 T-cell clones with Trizol (Invitrogen) and was reverse transcribed with 5' RACE PCR amplification of cDNA end (RACE, Invitrogen) using gene-specific primers, Ca-GSP2 (GGCTGCTCAGGGCGTA) and Cβ-GSP1 (GGCTGTCAGGGCGTA). DNA fragments containing the sequence encoding the CD8α T-cell clone’s α- or β-chains were obtained by 5' RACE PCR amplification of cDNA with combinations of the 5' RACE abridged anchor (Invitrogen) and gene-specific primers, Ca-GSP2 (GGCTGCTCAGGGCGTA) or Cβ-GSP2 (GTGGCCAGGCATACCAGTGT). Each PCR-derived α or β gene was cloned into pEGFP-N1 vector (Promega) and sequenced. Ten full-length genes were dropwise added into a microtube containing 470 µL of complete DMEM medium (Invitrogen). After the addition of 10 mL of complete DMEM medium containing 10% (v/v) FCS (Thermo Fisher Scientific, Cell Cultures) were transduced with vectors encoding the sequenced αβ TCRs (Table 1, Supplementary Fig. 4) or the control LC13 TCR. Retrovirus transduction was performed by first plating ~10^6 HEK 293 T cells in tissue culture plate in 10 mL of complete DMEM medium containing 10% (v/v) FCS (Thermo Fisher Scientific, Cell Cultures). Glutamax (2 mM), benzylpenicillin (100 U mL^{-1}) and streptomycin (100 µg mL^{-1}), 10% (v/v) FCS, 2 µg ml^{-1} HEPES buffer (10 mM), 2 µg ml^{-1} transferrin, 2 µg ml^{-1} sodium pyruvate (1 mM) and 1 x nonessential amino acids (all from Gibco), and were incubated overnight at 37 °C. 4 µg TCR 2A-linked/pMIG, 2 µg pVSV-G were transfected into HEK 293 T cells in tissue culture medium and incubated overnight at 37 °C. After 12 h incubation, HEK 293 T-cell culture medium containing retroviruses was carefully harvested and filtered through a 0.45 µm filter (Pall) to resuspend SKW3 cells and 10 µL Fugene 6 reagent (Roche), gently tapped to mix. The mixture was dropwise added into a microtube containing 470 µL OptiMEM medium (Invitrogen) and 30 µL Fugene 6 reagent (Roche), gently tapped to mix and incubated at room temperature for 15 min. The mixture was dropwise added to overnight-cultured HEK 293 T cells for plasmid co-transfection and further incubated overnight at 37 °C. Cell culture medium of the overnight transfection HEK 293 T cells was replaced with 10 mL of complete DMEM medium. About 10^4 SKW3 cells were seeded in tissue culture flask in 10 mL of complete DMEM medium and incubated overnight at 37 °C. After 12 h incubation, HEK 293 T-cell culture medium containing retroviruses was carefully harvested and filtered through a 0.45 µm filter (Pall) to reuspend SKW3 cells and 10 µL polybrene (6 mg

**Fig. 5** Conformational plasticity of the NY-ESO-1_{10-72} peptide dictates TCR recognition modes. a Side view of the NY-ESO-1_{10-72} peptide as presented for KFJ37 TCR-mediated recognition and b top view. c Side view of the NY-ESO-1_{10-72} peptide as presented for KFJS TCR-mediated recognition and d top view. HLA-B*07:02 shown as grey cartoon with the NY-ESO-1_{10-72} peptide shown as sticks coloured, blue and green for the KFJ37 TCR and KFJS TCR recognised peptides. e Overlay of the two NY-ESO-1_{10-72} peptide conformers with the carbon-a deviations shown for the entire peptide (f). The conserved interaction codon of the TRAV4/01 variable domain with the KFJ37 TCR and KFJS TCR coloured blue and green, respectively. Hydrogen and van der Waals bonds are shown by black and yellow lines with the conserved non-germline encoded Asp/Glu salt bridge also shown, in red.

**Tetramer dissociation assay** CD8+ T-cell clones (~10^6) were stained with NY-ESO-1_{10-72}, HLA-B*07:02 tetramer for an hour. Cells were then washed three times with ‘cold buffer’ [PBS (Gibco) containing 0.5% (w/v) bovine serum albumin (Gibco) and EDTA (2 mM, Sigma-Aldrich)] before being resuspended in RPMI-1640 with 10% (v/v) FCS medium containing unconjugated anti-HLA-B*07 (Serotec), and were incubated at 37 °C. At designated time points (0, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240 and 300 min), cells were harvested, washed for three times with cold buffer and stained with anti-CD8 (BD Biosciences) before flow cytometric analysis. The gating strategy used to analyse these cells is presented in Supplementary Fig. 6c.

**CD8 co-receptor dependence assay** CD8+ T-cell clones were blocked with unconjugated anti-CD8 (Serotec) for an hour. The treated CD8+ T-cell clones were incubated with or without P03-BLCL, an HLA-B*07:02+ Epstein-Barr virus transformed B-cell lymphoblastoid line (LICR) in 1:2 ratio in serially diluted NY-ESO-1_{10-72} peptide and BFA (10 µg mL^{-1}) for 5 h, followed by antibody staining and ICS (described above). Two other closely related assay conditions were set up for the same CD8+ T-cell clones without anti-CD8 blocking. The gating strategy used to analyse these cells is presented in Supplementary Fig. 6c.

**TCR clonotyping and anti TCR cell line generation** RNA was prepared from CD8+ T-cell clones with Trizol (Invitrogen) and was reverse transcribed with 5' rapid amplification of cDNA end (RACE, Invitrogen) using gene-specific primers, Ca-GSP1 (GGGAAGAAGGGTGTCTCCTGGAAT) and Cβ-GSP1 (GGCTGTCAGGGCGTA). DNA fragments containing the sequence encoding the CD8α T-cell clone’s α- or β-chains were obtained by 5' RACE PCR amplification of cDNA with combinations of the 5' RACE abridged anchor (Invitrogen) and gene-specific primers, Ca-GSP2 (GGCTGCTCAGGGCGTA) or Cβ-GSP2 (GTGGCCAGGCATACCAGTGT). Each PCR-derived α or β gene was cloned into pEGFP-N1 vector (Promega) and sequenced. Ten full-length genes were dropwise added into a microtube containing 470 µL OptiMEM medium (Invitrogen) and 30 µL Fugene 6 reagent (Roche), gently tapped to mix and incubated at room temperature for 15 min. The mixture was dropwise added to overnight-cultured HEK 293 T cells for plasmid co-transfection and further incubated overnight at 37 °C. Cell culture medium of the overnight transfection HEK 293 T cells was replaced with 10 mL of complete DMEM medium. About 10^4 SKW3 cells were seeded in tissue culture flask in 10 mL of complete DMEM medium and incubated overnight at 37 °C. After 12 h incubation, HEK 293 T-cell culture medium containing retroviruses was carefully harvested and filtered through a 0.45 µm filter (Pall) to reuspend SKW3 cells and 10 µL polybrene (6 mg

**ARTICLE**

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03321-w | www.nature.com/naturecommunications
protein expression and purification. Gene sequences encoding the functional NY-ESO-1αβ, -HLA-B*07:02-specific TCR α- and β-chains were engineered with the avian dysudal disulfide linkage in the constant region (KFJ4 TCR. Thr159Cys, Ser168Glu, Cys168Glu, Ala170Lys, KFJ5 TCR. Thr159Cys, Ser168Glu, Cys168Glu, Ala170Lys, KFJ15 TCR. Thr159Cys, Ser168Glu, Cys168Glu, Ala170Lys, KFJ37 TCR. Thr159Cys, Ser168Glu, Cys168Glu, Ala170Lys). Cotransfection of NY-ESO-1αβ and HLA-B*07:02 expression vector (Novagen). The KFJ4, KFJ5, KFJ15 and KFJ37 TCR heterodimers were expressed as inclusion bodies in BL21 Escherichia coli and solubilised in 8 M urea, 20 mM Tris–HCl pH 8.0 and 5 mM EDTA. TCR heterodimers were then washed three times with PBS, resuspended in complete DMEM and further incubated at 37 °C for 7–10 days. For TCRs that were not produced with peptide pulsed cells were kept as a control. Cells were then stained with antibodies specific to CD3 and CD69 (BD Biosciences), washed once with PBS and subsequently fixed in 1% (v/v) paraformaldehyde (EM) before flow cytometric analysis. The gating strategy used to analyse these cells is presented in Supplementary Fig. 6d.

Crystalisation and structure determination. All crystals were grown by the hanging-drop, vapour-diffusion method at 20 °C, crystals were flash-frozen in mother liquor supplemented with 30% (v/v) of the respective PEG, and data were collected at the Australian Synchrotron MXII beamline. Data were processed with the XDS program60 and were scaled with the SCALa6AVG. Iterative rounds of refinement were performed using Phenix.refine18,19. The electron density at the interface was clear and unambiguous. Initial structures were validated using the Protein Data Bank validation site and the coordinates relating to the data reported in this study were deposited in the protein data bank with identification codes 6ATS, 6AT6, 6AVG, 6AVF, respectively. All remaining data are available within the article and its Supplementary Information files and from the corresponding authors on reasonable request.

Received: 6 September 2017 Accepted: 6 February 2018
Published online: 12 March 2018

References

1. Rosenthal, J. et al. T cell antigen receptor recognition of antigen-presentation molecules. Annu. Rev. Immunol. 33, 169–200 (2015).
2. Joseph T.M., Grant E. & Gras S. Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity. Biol. Chem. 398, 1027–1036 (2017).
3. Pymm, P. et al. MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. Nat. Struct. Mol. Biol. 24, 387–394 (2017).
4. Collins, E. J., Garboczi, D. N. & Waley, D. C. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 371, 626–629 (1994).
5. McMurry, C. et al. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Cell. 5, e12536 (2016).
6. Burrows, S. R., Rosjohn, J. & McClusky, J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 27, 11–16 (2006).
7. Gras, S., Kjer-Nielsen, L., Burrows, S. R., McClusky, J. & Rosjohn, J. T-cell receptor bias and immunity. Curr. Opin. Immunol. 20, 119–125 (2008).
8. Bell, M. I. et al. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol. Immunol. 46, 1911–1917 (2009).
9. Miles, J. J., Douek, D. C. & Price, D. A. Bias in the TCR epitope spectrum relates to the data reported in this study were deposited in the protein data bank with identification codes 6ATS, 6AT6, 6AVG, 6AVF, respectively. All remaining data are available within the article and its Supplementary Information files and from the corresponding authors on reasonable request.
receptor engagement and T-cell immunodominance. J. Biol. Chem. 280, 23900–23909 (2005).
21. Wynn, K. K. et al. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 111, 4283–4292 (2008).
22. Bade-Döding, C. et al. The impact of human leukocyte antigen (HLA) microheterogeneity on ligand specificity within the HLA-B*44 allotypic family. Haematologica 96, 110–118 (2011).
23. Ekerache-Makinde, J. et al. Peptide length determines the outcome of TCR/peptide-MHC engagement. Blood 121, 1112–1123 (2013).
24. Rat, M. J. et al. HLA peptide length preferences control CD8+ T-cell responses. J. Immunol. 191, 561–571 (2013).
25. Hassan, C. et al. Naturally processed non-canonical HLA-A*02:01 presented peptide. J. Biol. Chem. 290, 2593–2603 (2015).
26. Stewart-Jones, G. B., McMichael, A. J., Bell, J. I., Stuart, D. I. & Jones, E. Y. A structural basis for immunodominant human T-cell receptor recognition. Nat. Immunol. 4, 657–663 (2003).
27. Turner, S. J. et al. Lack of prominent peptide–major histocompatibility complex features limits repertoire diversity in virus-specific CD8+ T-cell populations. Nat. Immunol. 6, 382–389 (2005).
28. Motomeo, G. et al. Molecular basis of a dominant T-cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01. J. Immunol. 192, 3428–3434 (2014).
29. Godfrey, D. I., Rossjohn, J. & McCluskey, J. The fidelity, occasional promiscuity, and versatility of T-cell receptor recognition. Immunity 28, 304–314 (2008).
30. Miles, J. J. et al. CTL recognition of a bulged viral peptide involves biased TCR selection. J. Immunol. 175, 3826–3834 (2005).
31. Gras, S. et al. Reversed T-cell receptor docking on a major histocompatibility class I complex limits involvement in the immune response. Immunity 45, 749–760 (2016).
32. Beringer, D. X. et al. T-cell receptor reversed polarity recognition of a self antigen major histocompatibility complex. Nat. Immunol. 16, 1153–1161 (2015).
33. Chen, W. & McClusky, J. Immunodominance and immunodominance: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95, 203–247 (2006).
34. Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B. & Schrier, P.I. Unexpected translation product of LAGE-1. J. Immunol. 188, 105 (2011).
35. Christopher Garcia, K., Adams, J. J., Feng, D. & Ely, L. K. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat. Immunol. 10, 143–147 (2009).
36. Yin, L., Scott-Browne, J., Kapppler, J. W., Capin, G. & Marrack, P. T cells and their eons-old obsession with MHC. Immunity 35, 49–60 (2011).
37. Seymour, A. E. et al. Correction of multi-gene deficiency in vivo using a single ‘self-claving’ 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589–594 (2004).
38. Berg, N. A. et al. The CDR3 regions of an immunodominant T-cell receptor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat. Immunol. 6, 171 (2005).
39. Kabsch, W. Integration, scaling, space-group assignment and post-refinement (Acta Crystallogr. D 66, 333–344 (2010).
40. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235–242 (2011).
41. Hennecke, J. & Wiley, D. C. Structure of a complex of the human αβ T cell receptor (TCR) HA1 T, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRB10101 and DRB10401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195, 571–581 (2002).
42. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352–367 (2012).
43. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).

Acknowledgements
We thank the Monash Macromolecular Crystallisation Facility staff for assistance with crystallisation, the staff at the Australian synchrotron for assistance with data collection and Hamish Halm, Kristy Campbell and Pascal Wilmann for technical assistance. This work was supported by the Australian Research Council, National Health and Medical Research Council, Ludwig Cancer Research and the Operational Infrastructure Support program of the Victorian State Government. S.G. is a Monash Senior Research Fellow. J.R. is supported by an ARC Laureate Fellowship.

Author contributions
K.F.C., B.S.G. and S.G. are joint authors who contributed equally. All the other authors contributed to the experiment design and analysis and writing of the manuscript. W.C. and J.R. are joint senior authors who oversaw the experimental design and analysis and writing of the manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-03321-w.

Competing interests: The authors declare no competing interests.
